Roche reaps promising results in Ph2 asthma study

Roche says that its experimental asthma drug, the IL-13 blocking antibody lebrikizumab, proved promising in a mid-stage clinical trial. Researchers said that the drug spurred in a "statistically significant increase in FEV1 (measure of lung function) in adults with asthma whose symptoms were inadequately controlled with inhaled corticosteroids." The results were published in the New England Journal of Medicine. Release

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.